Search
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
Senazodan
go.drugbank.com/drugs/DB19879ExperimentalThe usage of the INN stem '-dan' in the name indicates that Senazodan is a cardiac stimulant, pimobendan derivative. Senazodan has a monoisotopic molecular weight of 266.12 Da.
Adibendan
go.drugbank.com/drugs/DB20623ExperimentalThe usage of the INN stem '-dan' in the name indicates that Adibendan is a cardiac stimulant, pimobendan derivative. Adibendan has a monoisotopic molecular weight of 278.12 Da.
Nisoxetine
go.drugbank.com/drugs/DB09186ExperimentalIt was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.
CYT-6091
go.drugbank.com/drugs/DB05991ExperimentalCYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
Gold
go.drugbank.com/drugs/DB14154InvestigationalA yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration.
Fibrinolysin
go.drugbank.com/drugs/DB05254InvestigationalThe light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. … The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram.
Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.